Article open access publication

Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study

The Lancet Diabetes & Endocrinology, Elsevier, ISSN 2213-8587

Volume 2, 10, 2014

DOI:10.1016/s2213-8587(14)70146-9, Dimensions: pub.1020599652, PMC: PMC4196248, PMID: 25107467,



  1. (1) University of Cambridge, grid.5335.0
  2. (2) MRC Human Nutrition Research, grid.415055.0
  3. (3) German Institute of Human Nutrition, grid.418213.d
  4. (4) University of Oxford, grid.4991.5
  5. (5) Department of Epidemiology, Murcia Regional Health Council, Murcia, Spain
  6. (6) Institute of Health Carlos III, grid.413448.e
  7. (7) Instituto de Salud Pública de Navarra, grid.419126.9
  8. (8) University Medical Center Utrecht, grid.7692.a
  9. (9) Wageningen University & Research, grid.4818.5
  10. (10) Biodonostia, grid.432380.e
  11. (11) Public Health Division of Gipuzkoa, San Sebastian, Spain
  12. (12) Centre for research in epidemiology and population health, grid.463845.8
  13. (13) Institut Gustave Roussy, grid.14925.3b
  14. (14) University of Paris-Sud, grid.5842.b
  15. (15) Lund University, grid.4514.4
  16. (16) Umeå University, grid.12650.30
  17. (17) Catalan Institute of Oncology, grid.418701.b
  18. (18) Aarhus University, grid.7048.b, AU
  19. (19) German Cancer Research Center, grid.7497.d
  20. (20) University of Naples Federico II, grid.4691.a
  21. (21) Aalborg Hospital, grid.27530.33, North Denmark Region
  22. (22) Fondazione IRCCS Istituto Nazionale dei Tumori, grid.417893.0
  23. (23) Istituto per lo Studio e la Prevenzione Oncologica, grid.417623.5
  24. (24) Public Health Directorate, Asturias, Spain
  25. (25) Danish Cancer Society, grid.417390.8
  26. (26) Human Genetics Foundation, grid.428948.b
  27. (27) University of Turin, grid.7605.4
  28. (28) Andalusian School of Public Health, grid.413740.5
  29. (29) Instituto de Investigación Biosanitaria, grid.507088.2
  30. (30) International Agency For Research On Cancer, grid.17703.32
  31. (31) National Institute for Public Health and the Environment, grid.31147.30
  32. (32) University of Murcia, grid.10586.3a
  33. (33) Aire Onlus, Ragusa, Italy
  34. (34) Associazione Italiana Registri Tumori, Dipartimento di Prevenzione Medica, Azienda Sanitaria Provinciale, Ragusa, Italy
  35. (35) Imperial College London, grid.7445.2


BACKGROUND: Conflicting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. METHODS: The EPIC-InterAct case-cohort study includes 12,403 people with incident type 2 diabetes and a representative subcohort of 16,154 individuals who were selected from a cohort of 340.234 European participants with 3·99 million person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a random order by centre, and laboratory staff were masked to participant characteristics. We estimated country-specific hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox regression, which is weighted for case-cohort sampling, and pooled our findings using random-effects meta-analysis. FINDINGS: SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, different individual SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured (14:0 [myristic acid], 16:0 [palmitic acid], and 18:0 [stearic acid]) were positively associated with incident type 2 diabetes (HR [95% CI] per SD difference: myristic acid 1·15 [95% CI 1·09-1·22], palmitic acid 1·26 [1·15-1·37], and stearic acid 1·06 [1·00-1·13]). By contrast, measured odd-chain SFAs (15:0 [pentadecanoic acid] and 17:0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0·79 [0·73-0·85] for pentadecanoic acid and 0·67 [0·63-0·71] for heptadecanoic acid), as were measured longer-chain SFAs (20:0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0·72 to 0·81 (95% CIs ranging between 0·61 and 0·92). Our findings were robust to a range of sensitivity analyses. INTERPRETATION: Different individual plasma phospholipid SFAs were associated with incident type 2 diabetes in opposite directions, which suggests that SFAs are not homogeneous in their effects. Our findings emphasise the importance of the recognition of subtypes of these fatty acids. An improved understanding of differences in sources of individual SFAs from dietary intake versus endogenous metabolism is needed. FUNDING: EU FP6 programme, Medical Research Council Epidemiology Unit, Medical Research Council Human Nutrition Research, and Cambridge Lipidomics Biomarker Research Initiative.


Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

Aarhus University

Aalborg University

Dimensions Citation Indicators

Times Cited: 250

Field Citation Ratio (FCR): 61.17

Relative Citation ratio (RCR): 13.12

Open Access Info